MQX-503 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	6

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00577304 (ClinicalTrials.gov)	December 2007	18/12/2007	A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's ...	A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment an ...	Raynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Other Au ...	Drug: Nitroglycerin;Drug: Topical AmphiMatrix	MediQuest Therapeutics	NULL	Active, not recruiting	15 Years	70 Years	Both	200	Phase 3	United States
2	NCT00419419 (ClinicalTrials.gov)	December 2006	4/1/2007	Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon	Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo ...	Raynaud's Disease;Scleroderma;Autoimmune Diseases	Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)	MediQuest Therapeutics	NULL	Completed	18 Years	70 Years	Both	80	Phase 3	United States;Sweden;United Kingdom
3	EUCTR2005-004979-37-GB (EUCTR)	27/11/2006	18/09/2006	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placeb ...	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placeb ...	Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune ...	Product Name: MQX-503 Product Code: MQX-503 INN or Proposed INN: 10% Nitroglycerine in Propylene Glyco ...	MediQuest Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United Kingdom;Sweden
4	EUCTR2005-004979-37-SE (EUCTR)	27/10/2006	08/09/2006	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placeb ...	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placeb ...	Moderate to severe primary Raynaud’s,OR patients with Raynaud’s phenomenon secondary to autoimmune d ...	Product Name: MQX-503 Product Code: MQX-503 INN or Proposed INN: 10% Nitroglycerine in Propylene Glyco ...	MediQuest Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United Kingdom;Sweden
5	NCT00378521 (ClinicalTrials.gov)	July 2006	18/9/2006	Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon	Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatmen ...	Raynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Autoimmu ...	Drug: MQX-503	MediQuest Therapeutics	NULL	Completed	18 Years	75 Years	Both	15	Phase 2	United States
6	NCT00253331 (ClinicalTrials.gov)	November 2004	13/11/2005	Lab Study of MQX-503 in Treatment of Raynaud's	Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment ...	Raynaud Disease;Raynaud Disease Secondary to Scleroderma;Raynaud Secondary to Other Autoimmune Disea ...	Drug: topical organogel with nitroglycerin	MediQuest Therapeutics	NULL	Completed	18 Years	80 Years	Both	36	Phase 2/Phase 3	United States

First Previous1Next Last